The drug spurred about 10% weight loss over 10 months, though that finding came alongside high rates of gastrointestinal side ...

The funding deal is a vote of confidence in the sales potential of multiple prospects in late-stage development — one of ...

Vertex claimed the two drugs in the deal could eventually bring in more than $5 billion annually. Still, the high price it ...

Drug developers focusing on either disease area made up more than 40% of the number of biotech companies and amount raised so ...

As Greater Boston’s biotech industry sheds jobs, three unlikely regions are showing promise as up-and-coming hubs.

The California drugmaker, which has collaborations in place with Biogen, Sanofi and Eli Lilly, could be the 14th biotech to ...

The Phase 3 trial compared Roche’s divarasib with treatments sold by Amgen and Bristol Myers in patients with non-small cell ...

Celea, backed by investors such as RA Capital and Leaps by Bayer, is making what it says is an improved version of Roche's ...

Blair Jackson says the next 12 months may be the most important in Alkermes’ history, as the brain drugmaker races to join an ...

Biotech investors, executives and analysts worry that blanket bans on deals with Chinese companies could curb domestic ...

The influential CHMP committee also threw its support behind more than a dozen other medicines while recommending the ...

The company, which was built by Bain Capital, has now raised more than $426 million in its quest to advance a portfolio of ...